PH-dependent antigen-binding antibodies as a novel therapeutic modality

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 11, 2014, Pages 1943-1950

  Igawa, T ^a   Mimoto, F ^a   Hattori, K ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antibody engineering; Monoclonal antibody; pH dependent

Indexed keywords

ECULIZUMAB; FC RECEPTOR; HISTIDINE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CLONING; NONHUMAN; PH;

EID: 85027938012     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.08.003     Document Type: Review

References (45)

1. J.G. Elvin, R.G. Couston, and C.F. van der Walle Therapeutic antibodies: market considerations, disease targets and bioprocessing Int. J. Pharm. 440 2013 83 98
2. J.M. Reichert Which are the antibodies to watch in 2013? mAbs 5 2013 1 4
3. A.R. Bradbury, S. Sidhu, S. Dubel, and J. McCafferty Beyond natural antibodies: the power of in vitro display technologies Nat. Biotechnol. 29 2011 245 254
4. S.M. Lippow, K.D. Wittrup, and B. Tidor Computational design of antibody-affinity improvement beyond in vivo maturation Nat. Biotechnol. 25 2007 1171 1176
5. T. Igawa, H. Tsunoda, T. Tachibana, A. Maeda, F. Mimoto, C. Moriyama, M. Nanami, Y. Sekimori, Y. Nabuchi, Y. Aso, and K. Hattori Reduced elimination of IgG antibodies by engineering the variable region Protein Eng. Des. Sel. 23 2010 385 392
6. W.F. Dall'Acqua, P.A. Kiener, and H. Wu Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) J. Biol. Chem. 281 2006 23514 23524
7. J.R. Desjarlais, and G.A. Lazar Modulation of antibody effector function Exp. Cell Res. 317 2011 1278 1285
8. C. Spiess, J. Bevers III, J. Jackman, N. Chiang, G. Nakamura, M. Dillon, H. Liu, P. Molina, J.M. Elliott, W. Shatz, J.M. Scheer, G. Giese, J. Persson, Y. Zhang, M.S. Dennis, J. Giulianotti, P. Gupta, D. Reilly, E. Palma, J. Wang, E. Stefanich, H. Scheerens, G. Fuh, and L.C. Wu Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines J. Biol. Chem. 288 2013 26583 26593
9. A. Satta, D. Mezzanzanica, F. Turatti, S. Canevari, and M. Figini Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors Future Oncol. 9 2013 527 539
10. T. Kitazawa, T. Igawa, Z. Sampei, A. Muto, T. Kojima, T. Soeda, K. Yoshihashi, Y. Okuyama-Nishida, H. Saito, H. Tsunoda, T. Suzuki, H. Adachi, T. Miyazaki, S. Ishii, M. Kamata-Sakurai, T. Iida, A. Harada, K. Esaki, M. Funaki, C. Moriyama, E. Tanaka, Y. Kikuchi, T. Wakabayashi, M. Wada, M. Goto, T. Toyoda, A. Ueyama, S. Suzuki, K. Haraya, T. Tachibana, Y. Kawabe, M. Shima, A. Yoshioka, and K. Hattori A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model Nat. Med. 18 2012 1570 1574
11. Y. Ohsugi, and T. Kishimoto The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis Expert. Opin. Biol. Ther. 8 2008 669 681
12. M.A. Tabrizi, C.M. Tseng, and L.K. Roskos Elimination mechanisms of therapeutic monoclonal antibodies Drug Discov. Today 11 2006 81 88
13. M. Tabrizi, G.G. Bornstein, and H. Suria Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease AAPS J. 12 2010 33 43
14. S.K. Kelley, T. Gelzleichter, D. Xie, W.P. Lee, W.C. Darbonne, F. Qureshi, K. Kissler, E. Oflazoglu, and I.S. Grewal Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates Br. J. Pharmacol. 148 2006 1116 1123
15. N. Hayashi, Y. Tsukamoto, W.M. Sallas, and P.J. Lowe A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab Br. J. Clin. Pharmacol. 63 2007 548 561
16. K.M. Zareba Eculizumab: a novel therapy for paroxysmal nocturnal hemoglobinuria Drugs Today (Barc) 43 2007 539 546
17. J.J. Xiao, W. Krzyzanski, Y.M. Wang, H. Li, M.J. Rose, M. Ma, Y. Wu, B. Hinkle, and J.J. Perez-Ruixo Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys AAPS J. 12 2010 646 657
18. F.D. Finkelman, K.B. Madden, S.C. Morris, J.M. Holmes, N. Boiani, I.M. Katona, and C.R. Maliszewski Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes J. Immunol. 151 1993 1235 1244
19. Charles B. Davis, Leeann P. Tobia, Deborah C. Kwok, Christine M. Oishi, Neil Kheterpal, Timothy W. Hepburn, Lisa J. Benincosa, Fung-Sing Chow, and William J. Jusko Accumulation of antibody-target complexes and the pharmacodynamics of clotting after single intravenous administration of humanized anti-factor IX monoclonal antibody to rats Drug Deliv. 6 1999 171 179
20. T. Igawa, S. Ishii, T. Tachibana, A. Maeda, Y. Higuchi, S. Shimaoka, C. Moriyama, T. Watanabe, R. Takubo, Y. Doi, T. Wakabayashi, A. Hayasaka, S. Kadono, T. Miyazaki, K. Haraya, Y. Sekimori, T. Kojima, Y. Nabuchi, Y. Aso, Y. Kawabe, and K. Hattori Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Nat. Biotechnol. 28 2010 1203 1207
21. J. Chaparro-Riggers, H. Liang, R.M. DeVay, L. Bai, J.E. Sutton, W. Chen, T. Geng, K. Lindquist, M.G. Casas, L.M. Boustany, C.L. Brown, J. Chabot, B. Gomes, P. Garzone, A. Rossi, P. Strop, D. Shelton, J. Pons, and A. Rajpal Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 J. Biol. Chem. 287 2012 11090 11097
22. S.C. Devanaboyina, S.M. Lynch, R.J. Ober, S. Ram, D. Kim, A. Puig-Canto, S. Breen, S. Kasturirangan, S. Fowler, L. Peng, H. Zhong, L. Jermutus, H. Wu, C. Webster, E.S. Ward, and C. Gao The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics mAbs 5 2013 851 859
23. T. Igawa, A. Maeda, K. Haraya, T. Tachibana, Y. Iwayanagi, F. Mimoto, Y. Higuchi, S. Ishii, S. Tamba, N. Hironiwa, K. Nagano, T. Wakabayashi, H. Tsunoda, and K. Hattori Engineered monoclonal antibody with novel antigen-sweeping activity in vivo PLoS One 8 2013 e63236
24. J.P. Davda, and R.J. Hansen Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets mAbs 2 2010 576 588
25. J.J. Haringman, D.M. Gerlag, T.J. Smeets, D. Baeten, F. van den Bosch, B. Bresnihan, F.C. Breedveld, H.J. Dinant, F. Legay, H. Gram, P. Loetscher, R. Schmouder, T. Woodworth, and P.P. Tak A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis Arthritis Rheum. 54 2006 2387 2392
26. P.L. Martin, J. Cornacoff, U. Prabhakar, T. Lohr, G. Treacy, J.E. Sutherland, S. Hersey, and E. Martin Reviews preclinical safety and immune-modulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-alpha in cynomolgus macaques J. Immunotoxicol. 1 2005 131 139
27. J.C. Byrd, S. O'Brien, I.W. Flinn, T.J. Kipps, M. Weiss, K. Rai, T.S. Lin, J. Woodworth, D. Wynne, J. Reid, A. Molina, B. Leigh, and S. Harris Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia Clin. Cancer Res. 13 2007 4448 4455
28. G.C. Jayson, C. Mulatero, M. Ranson, J. Zweit, A. Jackson, L. Broughton, J. Wagstaff, L. Hakansson, G. Groenewegen, J. Lawrance, M. Tang, L. Wauk, D. Levitt, S. Marreaud, F.F. Lehmann, M. Herold, H. Zwierzina, and R. European Organisation for, C. Treatment of Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer Eur. J. Cancer 41 2005 555 563
29. T. Olafsen Fc engineering: serum half-life modulation through FcRn binding Methods Mol. Biol. 907 2012 537 556
30. C. Vaccaro, J. Zhou, R.J. Ober, and E.S. Ward Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels Nat. Biotechnol. 23 2005 1283 1288
31. R.J. Kurlander, D.M. Ellison, and J. Hall The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes J. Immunol. 133 1984 855 862
32. L.P. Ganesan, J. Kim, Y. Wu, S. Mohanty, G.S. Phillips, D.J. Birmingham, J.M. Robinson, and C.L. Anderson FcgammaRIIb on liver sinusoidal endothelium clears small immune complexes J. Immunol. 189 2012 4981 4988
33. C.Y. Zhang, and J.W. Booth Divergent intracellular sorting of Fc{gamma}RIIA and Fc{gamma}RIIB2 J. Biol. Chem. 285 2010 34250 34258
34. T. Lehrnbecher, C.B. Foster, S. Zhu, S.F. Leitman, L.R. Goldin, K. Huppi, and S.J. Chanock Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations Blood 94 1999 4220 4232
35. F. Mimoto, H. Katada, S. Kadono, T. Igawa, T. Kuramochi, M. Muraoka, Y. Wada, K. Haraya, T. Miyazaki, and K. Hattori Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and FcgammaRIIa(H131) Protein Eng. Des. Sel. 26 2013 589 598
36. K. Sato, M. Tsuchiya, J. Saldanha, Y. Koishihara, Y. Ohsugi, T. Kishimoto, and M.M. Bendig Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth Cancer Res. 53 1993 851 856
37. D.E. Vaughn, and P.J. Bjorkman Structural basis of pH-dependent antibody binding by the neonatal Fc receptor Structure 6 1998 63 73
38. S. Tickle, R. Adams, D. Brown, M. Griffiths, D. Lightwood, and A. Lawson High-throughput screening for high affinity antibodies JALA 14 2009 303 307
39. M.L. Murtaugh, S.W. Fanning, T.M. Sharma, A.M. Terry, and J.R. Horn A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches Protein Sci. 20 2011 1619 1631
40. J.V. Gerasimenko, A.V. Tepikin, O.H. Petersen, and O.V. Gerasimenko Calcium uptake via endocytosis with rapid release from acidifying endosomes Curr. Biol. 8 1998 1335 1338
41. E.M. Strauch, S.J. Fleishman, and D. Baker Computational design of a pH-sensitive IgG binding protein Proc. Natl. Acad. Sci. U. S. A. 111 2014 675 680
42. C.A. Sarkar, K. Lowenhaupt, T. Horan, T.C. Boone, B. Tidor, and D.A. Lauffenburger Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching" Nat. Biotechnol. 20 2002 908 913
43. C.E. Mogensen The glomerular permeability determined by dextran clearance using Sephadex gel filtration Scand. J. Clin. Lab. Invest. 21 1968 77 82
44. H. Feinberg, D. Torgersen, K. Drickamer, and W.I. Weis Mechanism of pH-dependent N-acetylgalactosamine binding by a functional mimic of the hepatocyte asialoglycoprotein receptor J. Biol. Chem. 275 2000 35176 35184
45. T. Yamamoto, H.C. Chen, E. Guigard, C.M. Kay, and R.O. Ryan Molecular studies of pH-dependent ligand interactions with the low-density lipoprotein receptor Biochemistry 47 2008 11647 11652